文献速递心律失常心力衰竭与心肌病

桥粒基因变异携带者的基因型特异性结局

Genotype-Specific Outcomes of Desmosomal Cardiomyopathies.
PubMed 文献 · Circulation · 2025-05-23

这项队列研究纳入533例桥粒基因变异携带者,随访分析发现16%发生危及生命的心律失常事件,3%发生终末期心衰;多变量分析显示,非截短型DSP变异、DSP与PKP2热点域错义变异、男性及双基因变异与心律失常风险升高相关。

要点

  • 双基因变异携带者心律失常与终末期心衰风险均显著升高。
  • 非截短型DSP变异与心律失常及终末期心衰风险升高相关。
  • 热点域错义变异(DSP、PKP2)增加危及生命心律失常风险。

核心结论

  • 在桥粒基因变异携带者中,基因型与心律失常及心衰结局相关,变异类型和位置进一步调节自然病史。

研究设计与样本

  • 队列研究,连续纳入因桥粒基因筛查转诊的患者,共533例携带者(59%男性,中位年龄39岁),来自214个家系。

主要发现

  • 533例中83例(16%)发生危及生命心律失常事件,发生年龄中位数40岁。
  • 533例中14例(3%)发生终末期心衰,发生年龄中位数57岁。
  • 与参考组相比,非截短型DSP变异(HR 5.0,95%CI 1.5-18.2;P=0.009)和双基因变异(HR 4.7,95%CI 1.0-19.3;P=0.044)与终末期心衰风险升高相关。

关键数值与推荐

  • 危及生命心律失常事件定义为心源性猝死、心脏骤停复苏成功或血流动力学不稳定的室性心动过速。
  • 终末期心衰结局定义为致命性心衰事件或心脏移植的复合终点。
  • 与非截短型PKP2变异相比,非截短型DSP变异(HR 2.3,95%CI 1.3-4.1;P=0.008)与心律失常风险升高相关。
  • 与非截短型PKP2变异相比,DSP热点域错义变异(HR 2.7,95%CI 1.2-6.2;P=0.010)和PKP2热点域错义变异(HR 3.6,95%CI 2.0-6.5;P<0.001)与心律失常风险升高相关。
  • 男性(HR 1.7,95%CI 1.1-2.8;P=0.021)和双基因变异(HR 3.4,95%CI 1.7-6.9;P<0.001)与心律失常风险升高相关。

临床怎么用

  • 对桥粒基因变异携带者进行风险分层时,应综合考虑基因型(DSP与PKP2)、变异类型(非截短型与错义)、热点域位置、性别及是否双基因变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Desmosomal gene variants (DGVs) have been associated with a diverse spectrum of phenotypic manifestations within arrhythmogenic cardiomyopathy, but data on genotype-specific outcomes are lacking. We investigated genotype-specific arrhythmic and heart failure (HF) outcomes in DGV carriers. METHODS: This cohort study included consecutive patients referred for screening for desmosomal genes. Carriers of pathogenic and rare (allele frequency <10-4) variants of uncertain significance were included. The arrhythmic end point was the occurrence of a life-threatening arrhythmic event, defined as sudden cardiac death, aborted cardiac arrest, or hemodynamically unstable ventricular tachycardia. The end-stage HF outcome was the composite of a fatal HF episode or cardiac transplantation. RESULTS: We included 533 DGV carriers (59% male; median [interquartile range] age, 39 [22-54] years) from 214 families: 503 of 533 (94%) had a single DGV (212 [40%] PKP2, 160 [30%] DSP, 97 [18%] DSG2, 34 [6%] DSC2) and 30 of 533 (6%) double DGVs. Overall, 83 of 533 (16%) experienced a life-threatening arrhythmic event (at age 40 [33-51] years), and 14 of 533 (3%) experienced end-stage HF (at age 57 [50-60] years). Multivariable analysis demonstrated that, compared with nonmissense PKP2 variants, nonmissense DSP variants (hazard ratio [HR], 2.3 [95% CI, 1.3-4.1]; P=0.008), missense variants in hotspot domains in DSP (HR, 2.7 [95% CI, 1.2-6.2]; P=0.010) and PKP2 (HR, 3.6 [95% CI, 2.0-6.5]; P<0.001), male sex (HR, 1.7 [95% CI, 1.1-2.8]; P=0.021), and double DGVs (HR, 3.4 [95% CI, 1.7-6.9]; P<0.001) were associated with a higher risk of a life-threatening arrhythmic event. Nonmissense DSP variants (HR, 5.0 [95% CI, 1.5-18.2]; P=0.009) and double DGVs (HR, 4.7 [95% CI, 1.0-19.3]; P=0.044) were also associated with increased risk of end-stage HF. CONCLUSIONS: Among carriers of DGVs, genotype was associated with arrhythmic and HF outcomes, with type and location of the variant further modulating the natural history.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Pergola V, Trancuccio A, Kukavica D, et al. Genotype-Specific Outcomes of Desmosomal Cardiomyopathies. Circulation. 2025. PMID: 40406876. doi:10.1161/CIRCULATIONAHA.124.073475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。